Physician profile
James J Brennan
NPI 1447217666
$129,740.54
in general payments reported to CMS, 2019-2025
13 companies · $2,796 in 2025
The $2,796 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $26K · 2021: $25K · 2022: $24K · 2023: $14K · 2024: $2,985 · 2025: $2,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $10K · Consulting Fee: $4,750 · Food and Beverage: $2,320 · Travel and Lodging: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $10,262.04 |
| Consulting Fee | $4,750.00 |
| Food and Beverage | $2,320.37 |
| Travel and Lodging | $2,079.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seaspine Orthopedics Corporation | $104,032.62 | 2019-2022 | |
| Orthofix Medical, INC. | $17,228.74 | 2023-2025 | Sierra, Mariner, Manta Ray |
| Boston Scientific Corporation | $7,607.97 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Spectra Wavewriter |
| Medtronic, INC. | $333.96 | 2021-2025 | Stealthstation S8 Platform, Intellis Adaptivestim |
| Intrinsic Therapeutics | $239.17 | 2025 | Barricaid Acd (Annular Closure Device) |
| Cerapedics INC. | $91.90 | 2024-2025 | I-Factor Peptide Enhanced Bone Graft |
| Spr Therapeutics, INC | $80.81 | 2024 | Sprint Pns System |
| Microtransponder, INC. | $32.20 | 2025 | |
| Shire North American Group INC | $22.82 | 2019 | |
| Misonix INC | $22.34 | 2019 | |
| Mannkind Corporation | $21.75 | 2022 | |
| Saluda Medical Americas, INC. | $13.47 | 2025 | Evoke |
| Clarus Therapeutics INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.